By Megan Martin, NCCN Communications Manager
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) have been further recognized as the global standard in oncology with the announcement that select NCCN Guidelines™ are being translated into Japanese. The Translational Research Informatics Center (TRI) Foundation for Biomedical Research and Innovation, under the supervision of the Japanese Society for Cancer of the Colon and Rectum, has translated the NCCN Guidelines for Colon Cancer and Rectal Cancer, which are now available online. In addition, translations of the NCCN Guidelines for Anal Carcinoma and Colorectal Cancer Screening will be published shortly.
“NCCN is pleased to be able to collaborate with clinicians in Japan in determining appropriate and effective avenues of care for their oncology patients,” said William T. McGivney, PhD, Chief Executive Officer of NCCN. “As the arbiter of high-quality cancer care, NCCN remains dedicated to enhancing our international relationships to improve the quality, effectiveness, and efficiency of oncology practice so patients worldwide can live better lives.”
Cancer is the leading cause of death in Japan, with one person out of three dying of the disease according to the Japan Cancer Society. Colon cancer is the third leading cause of cancer deaths among the Japanese following lung and stomach cancers.
“In Japan, more than 500,000 people are diagnosed with cancer each year and more than 335,000 die from the disease every year,” said Masanori Fukushima, MD, PhD, Professor Emeritus, Kyoto University, Director and Chairman of TRI. “Consequently, by aligning with NCCN to provide our clinicians with treatment recommendations developed by world-renowned experts in cancer, we look to improve the care provided to patients and impact the number of cancer survivors in Japan.”
NCCN’s international collaborations continue to grow fostered by the demand for the development and publication of foreign editions of the NCCN Guidelines. These editions are either direct translations of the NCCN Guidelines into a foreign language, as with Japan, or modified versions of the NCCN Guidelines to take into consideration metabolic differences in populations, accessibility of technology, and/or the regulatory status of health care technologies used in cancer management in the specified country. Foreign editions of the NCCN Guidelines are developed by the host country’s oncology thought leaders in conjunction with NCCN Guidelines Panel Chairs or Members to ensure consistency and accuracy.
Additional Japanese translations of the NCCN Guidelines in the areas of urological cancers will be developed throughout 2010.